Commercial Hormone Replacement Therapy Jeopardized Proinflammatory Factors in Experimental Rat Models

Mohammed Ali; Isam H. Mahmood

doi:10.3889/oamjms.2022.9924

Authors

Mohammed Ali Department of Pharmacy, Al-Jumhory Teaching Hospital, Mosul, Iraq
Isam H. Mahmood Department of Pharmacy, Al-Noor University College, Ninevah, Iraq

DOI:

https://doi.org/10.3889/oamjms.2022.9924

Keywords:

Estrogen, Progesterone, Contraception, Hormone replacement, Interleukin, Systemic inflammation

Abstract

BACKGROUND: Hormonal contraceptive therapy is considered the easiest and most convenient contraceptive method. Commercially, available contraceptive combination differs in their composition and concentration of combined constituents. These variations make some of these products preferred over others by consumers based on their side effects profile.

AIM: The objective of the current research was to ascertain the proinflammatory influences of commercially available products.

METHODS: To do so, five groups of rats (ten rats in each group) were exposed to Microgynon, Depo-Provera, marvel on, and Yasmin compared to the control non-treated group. We measured proinflammatory markers including d-dimer, TNF-α (tumor necrosis factor-alpha), IL (interleukin)-6, IL (interleukin)-1B, and c-reactive protein.

RESULTS: The results confirmed that Yasmin has induced the most deleterious effects on proinflammatory markers indicated by significant elevation of IL1B.

CONCLUSION: Hormone replacement therapy should be critically indicated and precautions raised inpatient with subclinical diseases, especially cardiovascular ones.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal estrogen/progestin interventions study. Circulation. 1999;100(7):717-22. https://doi.org/10.1161/01.CIR.100.7.717 PMid:10449693 DOI: https://doi.org/10.1161/01.CIR.100.7.717

Herrington DM, Brosnihan KB, Pusser BE, Seely EW, Ridker PM, Rifai N, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab. 2001;86(9):4216-22. https://doi.org/10.1210/jcem.86.9.7799 PMid:11549652 DOI: https://doi.org/10.1210/jcem.86.9.7799

Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 2004;24(3):571-6. https://doi.org/10.1161/01.ATV.0000115383.49802.0c PMid:14699021 DOI: https://doi.org/10.1161/01.ATV.0000115383.49802.0c

Sunday L, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab. 2006;291(2):E261-7. https://doi.org/10.1152/ajpendo.00550.2005 PMid:16492687 DOI: https://doi.org/10.1152/ajpendo.00550.2005

Rosano GM, Webb CM, Chierchia S, Morgani LG, Gabraele M, Sarrel PM, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154-9. https://dog.org/10.1016/S0735-1097(00)01007-X PMid:11127455 DOI: https://doi.org/10.1016/S0735-1097(00)01007-X

Aksoy AN, Toker A, Celık M, Aksoy M, Halıcı Z, Aksoy H. The effect of progesterone on systemic inflammation and oxidative stress in the rat model of sepsis. Indian J Pharmacol. 2014;46(6):622-6. https://doi.org/10.4103/0253-7613.144922 PMid:25538334 DOI: https://doi.org/10.4103/0253-7613.144922

Pfeilschifter J, Köditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23(1):90-119. https://doi.org/10.1210/edrv.23.1.0456 PMid:11844745 DOI: https://doi.org/10.1210/edrv.23.1.0456

Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men. Lancet. 1992;339(8795):702-6. https://doi.org/10.1016/0140-6736(92)90599-X PMid:1347584 DOI: https://doi.org/10.1016/0140-6736(92)90599-X

Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583-612. https://doi.org/10.1161/01.CIR.90.1.583 PMid:8026046 DOI: https://doi.org/10.1161/01.CIR.90.1.583

Hurn PD, Brass LM. Estrogen and stroke: A balanced analysis. Stroke. 2003;34(2):338-41. https://doi.org/10.1161/01.STR.0000054051.88378.25 PMid:12574529 DOI: https://doi.org/10.1161/01.STR.0000054051.88378.25

Brass LM. Hormone replacement therapy and stroke: Clinical trials review. Stroke. 2004;35(11 Suppl 1):2644-7. https://doi.org/10.1161/01.STR.0000143218.20061.ac PMid:15459443 DOI: https://doi.org/10.1161/01.STR.0000143218.20061.ac

Hulley S, Grady D, Bush T, Furberg C, Riggs B, Herrington D, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Obst Gynecol Surv. 1999;54(1):41-2. https://doi.org/10.1001/jama.280.7.605 PMid:9718051 DOI: https://doi.org/10.1097/00006254-199901000-00022

McCullough LD, Hurn PD. Estrogen and ischemic neuroprotection: An integrated view. Trends Endocrinol Metab. 2003;14(5):228-35. https://doi.org/10.1016/S1043-2760(03)00076-6 PMid:12826329 DOI: https://doi.org/10.1016/S1043-2760(03)00076-6

Clarkson TB. Progestogens and cardiovascular disease. A critical review. J Reprod Med. 1999;44(Suppl 2):180-4. PMid:11392029

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321-33. https://doi.org/10.1001/jama.288.3.321 PMid:12117397 DOI: https://doi.org/10.1001/jama.288.3.321

Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The heart and estrogen-progestin replacement study. Circulation. 2001;103(5):638-42. https://doi.org/10.1161/01.CIR.103.5.638 PMid:11156873 DOI: https://doi.org/10.1161/01.CIR.103.5.638

De Vries HE, Kuiper J, Boer AG, Berkel TJ, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev. 1997;49(2):143-56. PMid:9228664

Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000;10(1):95-112. https://doi.org/10.1111/j.1750-3639.2000.tb00247.x PMid:10668900 DOI: https://doi.org/10.1111/j.1750-3639.2000.tb00247.x

McKay LI, Cidlowski JA. Molecular control of immune/ inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev. 1999;20(4):435-59. https://doi.org/10.1210/edrv.20.4.0375 PMid:10453354 DOI: https://doi.org/10.1210/edrv.20.4.0375

Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Nat Acad Sci U S A. 1998;95(18):10966-71. https://doi.org/10.1073/pnas.95.18.10966 PMid:9724813 DOI: https://doi.org/10.1073/pnas.95.18.10966

Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol. 1999;98(1):9-14. https://doi.org/10.1007/s004010051045 PMid:10412795 DOI: https://doi.org/10.1007/s004010051045

Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci. 1997;17(23):9157-64. https://doi.org/10.1523/JNEUROSCI.17-23-09157.1997 PMid:9364062 DOI: https://doi.org/10.1523/JNEUROSCI.17-23-09157.1997

Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res. 1998;118:215-29. https://doi.org/10.1016/S0079-6123(08)63210-0 PMid:9932444 DOI: https://doi.org/10.1016/S0079-6123(08)63210-0

Ospina JA, Brevig HN, Krause DN, Duckles SP. Estrogen suppresses IL-1β-mediated induction of COX-2 pathway in rat cerebral blood vessels. Am J Physiol Heart Cir Physiol. 2004;286(5):H2010-9. https://doi.org/10.1152/ajpheart.00481.2003 PMid: 14684367 DOI: https://doi.org/10.1152/ajpheart.00481.2003

McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke. 2002;33(6):1685-91. https://doi.org/10.1161/01.STR.0000016325.54374.93 PMid:12053012 DOI: https://doi.org/10.1161/01.STR.0000016325.54374.93

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701-12. https://doi.org/10.1001/jama.291.14.1701 PMid:15082697 DOI: https://doi.org/10.1001/jama.291.14.1701

Abdulqader SW, Faisal MI, Saeed MG, Merkhan MM. Fluvoxamine suppressed oxidative stress associated with tissue Erosion. Res J Pharmacy Technol. 2022;15(2):819-4. https://doi.org/10.5958/0974-360X DOI: https://doi.org/10.52711/0974-360X.2022.00136

Abdulqader SW, Faisal IM, Saeed MG, Merkhan MM. Fluvoxamine provide a gastro-protection against vitiated insult. Indian J Forensic Med Toxicol. 2022;16(1):1047. https://doi.org/10.37506/ijfmt.v16i1.17633 DOI: https://doi.org/10.37506/ijfmt.v16i1.17633

Baal MW, Kenemans P, Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999;81(06):925-8. https://doi.org/10.1055/s-0037-1614600 PMid:10404769 DOI: https://doi.org/10.1055/s-0037-1614600

Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100(7):713-6. https://doi.org/10.1161/01.CIR.100.7.713 PMid:10449692 DOI: https://doi.org/10.1161/01.CIR.100.7.713

Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19(4):893-9. https://doi.org/10.1161/01.ATV.19.4.893 PMiD:10195915 DOI: https://doi.org/10.1161/01.ATV.19.4.893

Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med. 1993;36(4):611-22. https://dog.org/10.1353/pbm.1993.0004 PMid:8361844 DOI: https://doi.org/10.1353/pbm.1993.0004

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9. https://doi.org/10.1056/NEJM199704033361401 PMid:9077376 DOI: https://doi.org/10.1056/NEJM199704033361401

Tracy RP, Lemaitre RN, Psaty BM, Evans RW, Ives DG, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997;17(6):1121-7. https://doi.org/10.1161/01.ATV.17.6.1121 PMid:9194763 DOI: https://doi.org/10.1161/01.ATV.17.6.1121

Toss H, Lindahl B, Siegbahn A, Wallentin L, Group FT. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96(12):4204-10. https://doi.org/10.1161/01.CIR.96.12.4204 PMid:9416883 DOI: https://doi.org/10.1161/01.CIR.96.12.4204

Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98(9):839-44. https://doi.org/10.1161/01.CIR.98.9.839 PMid:9738637 DOI: https://doi.org/10.1161/01.CIR.98.9.839

Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA augsburg cohort study, 1984 to 1992. Circulation. 1999;99(2):237-42. https://doi.org/10.1161/01.CIR.99.2.237 PMid:9892589 DOI: https://doi.org/10.1161/01.CIR.99.2.237

Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417-24. https://doi.org/10.1056/NEJM199408183310701 PMid:7880233 DOI: https://doi.org/10.1056/NEJM199408183310701

Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58. https://doi.org/10.1046/j.1523-1755.1999.00273.x PMid:9987089 DOI: https://doi.org/10.1046/j.1523-1755.1999.00273.x

Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the women’s health initiative observational study. JAMA. 2002;288(8):980-7. https://doi.org/10.1001/jama.288.8.980 PMid:12190368 DOI: https://doi.org/10.1001/jama.288.8.980

Lacut K, Oger E, Gal LG, Blouch MT, Abgrall JF, Kerlan V, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003;90(07):124-31. https://doi.org/10.1055/s-0037-1613608 PMid:12876635 DOI: https://doi.org/10.1055/s-0037-1613608

Brooks-Asplund EM, Tupper CE, Daun JM, Kenney WL, Cannon JG. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine. 2002;19(4):193-200. https://doi.org/10.1006/cyto.2002.1963 PMid:12297113 DOI: https://doi.org/10.1006/cyto.2002.1963

Jiang C, Wang J, Li X, Liu C, Chen N, Hao Y. Progesterone exerts neuroprotective effects by inhibiting inflammatory response after stroke. Inflamm Res. 2009;58(9):619-24. https://doi.org/10.1007/s00011-009-0032-8 PMid:19333725 DOI: https://doi.org/10.1007/s00011-009-0032-8

Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: Neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17(5):367-88. https://doi.org/10.1089/neu.2000.17.367 PMid:10833057 DOI: https://doi.org/10.1089/neu.2000.17.367

Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol. 2008;29(4):507-19. https://doi.org/10.1016/j.yfrne.2008.04.001 PMid:18522863 DOI: https://doi.org/10.1016/j.yfrne.2008.04.001

Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: Mechanisms and nonreproductive functions. Annu Rev Physiol. 2004;66:291-313. https://doi.org/10.1146/ annurev.physiol.66.032802.154945 PMid:14977405 DOI: https://doi.org/10.1146/annurev.physiol.66.032802.154945